Thus, a better understanding of the mechanisms for evading resistance to the HER2-targeted therapies through the PI3K/AKT/mTOR/MAPK pathways is needed to improve outcomes in BC patients with PIK3CA mutations [159]. This evidence concerns the gene PIK3CG and breast cancer.